Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF59-adjuvanted vs Inactivated Influenza Vaccine in Naive Infants
NCT03669627Phase 2Completed
- Sponsor
- Canadian Immunization Research Network
- Start
- Nov 2018
- Primary completion
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Fluzone Trivalent in influenza (3 arms), sponsored by Canadian Immunization Research Network. Primary endpoint: Serum Hemagglutination Inhibition Antibody Titers at Day 393. Started Nov 2018; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03669627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03669627.